On October 30, 2020, the Board of Directors of Marizyme, Inc. with an effective date of November 1, 2020, the Board appointed Dr. Neil J. Campbell as president and director of the Marizyme. Dr. Campbell has an extensive background in life sciences and management. James Sapirstein, the interim chief executive officer, will depart his interim role on November 1, 2020 and resume his role as chairman. Dr. Satish Chandran will relinquish his title as president and chief operating officer and will assume his new role as co-founder and chief technology officer.
Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Companyâs product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.
MARIZYME, INC. 
